Krystal Biotech, Inc. $KRYS Stock: Profund Advisors LLC Boosts Position

Profund Advisors LLC boosted its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 26.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,313 shares of the company’s stock after acquiring an additional 1,543 shares during the period. Profund Advisors LLC’s holdings in Krystal Biotech were worth $2,432,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Silvant Capital Management LLC bought a new stake in shares of Krystal Biotech in the 2nd quarter worth approximately $30,000. Western Wealth Management LLC bought a new stake in shares of Krystal Biotech in the first quarter valued at $34,000. USA Financial Formulas bought a new stake in shares of Krystal Biotech in the first quarter valued at $44,000. Integrated Wealth Concepts LLC purchased a new position in shares of Krystal Biotech during the 2nd quarter valued at $46,000. Finally, Signaturefd LLC lifted its position in shares of Krystal Biotech by 27.3% during the 3rd quarter. Signaturefd LLC now owns 168 shares of the company’s stock valued at $56,000 after buying an additional 36 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $332.29 on Monday. Krystal Biotech, Inc. has a 1-year low of $184.02 and a 1-year high of $382.54. The stock has a 50-day moving average of $337.46 and a 200-day moving average of $308.68. The firm has a market cap of $9.84 billion, a PE ratio of 41.64 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 2nd. The company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.26. The company had revenue of $127.34 million during the quarter, compared to analyst estimates of $125.77 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. As a group, equities research analysts forecast that Krystal Biotech, Inc. will post 7.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on KRYS shares. Jefferies Financial Group reissued a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a report on Monday, July 13th. Citigroup reiterated a “buy” rating on shares of Krystal Biotech in a research report on Thursday, October 15th. HC Wainwright reiterated a “buy” rating and issued a $361.00 target price on shares of Krystal Biotech in a research note on Thursday, October 15th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Wednesday, September 23rd. Finally, Royal Bank Of Canada began coverage on shares of Krystal Biotech in a report on Friday, August 14th. They set an “outperform” rating and a $400.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Krystal Biotech has a consensus rating of “Moderate Buy” and an average target price of $377.20.

Insider Buying and Selling

In other news, Director Dino A. Rossi sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the transaction, the director owned 50,000 shares in the company, valued at $16,456,000. This trade represents a 33.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the transaction, the insider owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.